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Abstract
Background: After the availability of the results of validation studies, the sentinel lymph node biopsy (SLNB) has
replaced routine axillary dissection (AD) as the new standard of care in early unifocal breast cancers. Multifocal
(MF) and multicentric (MC) tumors have been considered a contraindication for this technique due to the possible
incidence of a higher false-negative rate. This prospective study evaluates the lymphatic drainage from different
tumoral foci of the breast and assesses the accuracy of SLNB in MF-MC breast cancer.
Patients and methods: Patients with preoperative diagnosis of MF or MC infiltrating and clinically node-
negative (cN0) breast carcinoma were enrolled in this study. Two consecutive groups of patients underwent SLN
mapping using a different site of injection of the radioisotope tracer: a) "2ID" Group received two intradermal
(ID) injections over the site of the two dominant neoplastic nodules. A lymphoscintigraphic study was performed
after each injection to evaluate the route of lymphatic spreading from different sites of the breast. b) "A" Group
had periareolar (A) injection followed by a conventional lymphoscintigraphy. At surgery, both radioguided SLNB
(with frozen section exam) and subsequent AD were planned, regardless the SLN status.
Results: A total 31 patients with MF (n = 12) or MC (n = 19) invasive, cN0 cancer of the breast fulfil the selection
criteria. In 2 ID Group (n = 15) the lymphoscintigraphic study showed the lymphatic pathways from two different
sites of the breast which converged into one major lymphatic trunk affering to the same SLN(s) in 14 (93.3%)
cases. In one (6.7%) MC cancer two different pathways were found, each of them affering to a different SLN. In
A Group (n = 16) lymphoscintigraphy showed one (93.7%) or two (6.3%) lymphatic channels, each connecting
areola with one or more SLN(s). Identification rate of SLN was 100% in both Groups. Accuracy of frozen section
exam on SLN was 96.8% (1 case of micrometastasis was missed). SLN was positive in 13 (41.9%) of 31 patients,
including 4 cases (30.7%) of micrometastasis. In 7 of 13 (53.8%) patients the SLN was the only site of axillary
metastasis. SLNB accuracy was 96.8% (30 of 31), sensitivity 92.8 (13 of 14), and false-negative rate 7.1% (1 of 14).
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Since the case of skip metastasis was identified by the surgeon intraoperatively, it would have been no impact in
the clinical practice.
Conclusion: Our lymphoscintigraphic study shows that axillary SLN represents the whole breast regardless of
tumor location within the parenchyma. The high accuracy of SLNB in MF and MC breast cancer demonstrates,
according with the results of other series published in the literature, that both MF and MC tumors do not
represent a contraindication for SLNB anymore.
Background
During the last few years world-wide consensus has been
obtained for SLNB as new standard of axillary staging in
early breast cancer. According to the International Con-
sensus Conference on SLNB (Philadelphia, 2001) [1] the
technique is indicated for unifocal, infiltrating and clini-
cally node-negative breast carcinoma up to 3 cm in diam-
eter. Absolute or relative contraindications include
pregnancy, tumors downstaged by neoadjuvant chemo-
therapy, previous breast or axillary surgery, some cases of
multifocality (once total diameter of the breast quadrant
involved by cancer is greater than 3 or 5 cm) and multi-
centricity [1].
Recently, both European and United States guidelines on
breast cancer treatment have included SLNB as first choice
option for early infiltrating, unifocal and clinically node-
negative lesions, providing that such procedure is per-
formed by experienced surgeons [2-4]. However, several
limits for application of this technique have been recently
revised [5] in order to extend the potential benefit of
avoiding unnecessary axillary dissection. The role of SLNB
in multifocal (MF) and multicentric (MC) breast cancer is
one of the most common topic open to debate.
Although the terms MF and MC have often been used to
identify the same condition, MC cancer should be defined
as multiple synchronous tumors originating in different
sites of the breast, and MF cancer as multiple foci of the
same tumor.
Over the past few years, several clinical and anatomical
criteria have been proposed to identify MF and MC can-
cers, including the distance between cancer, foci (greater
than 2, 3 or 5 cm in MC cancer), the presence of histolog-
ically normal tissue among nodules (MC), the location in
the same (MF) or different (MC) quadrants of the breast
[6,7].
During early diffusion of the SLNB technique the main
theory of lymphatic drainage of the breast postulated the
presence of multiple pathways connecting different sites
of the breast to different SLNs. As consequence, both MF
and MC breast cancers were considered relative (MF) or
absolute (MC) contraindications to SLNB [1] due to con-
cerns about the possibility to identify the "true" SLN.
Moreover, earlier results of validation studies on SLNB
technique suggested the possible incidence of a higher
false-negative rate in MF and MC cancers [8]. Neverthe-
less, recent studies support now a different theory about
breast lymphatic drainage: the SLN (one or more SLNs)
would be representative of the whole breast, considered as
a single limphatic unit [9,10]. In this case, SLNB tech-
nique in MF and MC cancers should be as accurate as in
unifocal breast tumors [11].
This prospective study was designed to evaluate the lym-
phatic drainage from different tumoral foci of the breast
and to assess the accuracy of the SLNB in MF and MC inva-
sive breast cancers.
Patients and methods
Patients with preoperative diagnosis of MF or MC breast
carcinoma were prospectively enrolled in this study. Cases
of suspicious MF and MC tumors identified after clinical,
mammographic and echographic assessment had to be
confirmed by positive fine needle aspiration cytology
(FNAC) or core biopsy histology in at least two of the nod-
ules; cases with one positive lesion associated with other
suspicious nodules with athypical cells on FNAC were
also included in the study.
Breast cancer was defined as MF if two or more lesions
were located in the same quadrant and distance from each
other less than 5 cm. If nodules arises in different quad-
rants of the breast and/or were distant each other more
than 5 cm the cancer was defined as MC. Exclusion criteria
were: ductal or lobular in situ carcinomas, clinical and/or
echographic evidence of positive axilla, neoadjuvant
chemotherapy, previous breast or axillary surgery or radi-
otherapy. Although tumor size greater than 3 or 5 cm is
considered a contraindication for SLNB in most guide-
lines, T2–T3 cancers were included in this study due to
recent reports of high accuracy of SLNB even in these cases
[12].
Written informed consent was required to include
patients in this study and approval from the Ethical Com-
mittee of the Hospital was obtained.
The day before surgery SLN mapping was performed using
the radioisotope technique [13]. All patients were injectedWorld Journal of Surgical Oncology 2006, 4:79 http://www.wjso.com/content/4/1/79
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with 20–40 mBq of 99mTc-nanocolloid (< 100 nm in
diameter), but in two consecutive groups of patients a dif-
ferent site of injection was used. 1) 2ID Group. A former
series of patients was designed to receive two consecutive
intradermal (2ID) injections of the tracer [14] in the cuta-
neous projections corresponding to the deep site of each
nodule (in patients with more than two nodules, injec-
tions were performed over the two dominant lesions most
distant to each other). In case of non-palpable tumor the
technique of radio-guided localization (ROLL) under
ultrasonography (US) or stereotaxis was used. During the
procedure, the cutaneous projection of the non-palpable
lesions was also marked on the skin in order to guide the
intradermal injection of the tracer during SLN mapping.
After each tracer injection a lymphoscintigraphic study
was planned to evaluate the route of lymphatic spreading
from different sites of the breast. The imaging protocol
included: 1) early imaging (after 5 minutes) showing the
lymphatic route from the site of injection to the SLN; 2)
late imaging (after 30 minutes) demonstrating the pres-
ence and the number of the SLN(s) identified. Both
images were performed with shelded injection site and
after positioning of a low activity 57Co-flood source in
order to obtain the body outline. The lymphoscinti-
graphic images performed after both the first and the sec-
ond intradermal injections were then compared in order
to recognized if the identified lymphatic route and SLN(s)
were coincident or not. 2) A Group. In the subsequent
group of women included in this study a periareolar (A)
injection technique as described by other authors [15] was
used, followed by a preoperative lymphoscintigraphy
with early (5 minutes) and late (30 minutes) imaging.
Whenever possible, breast surgery was conservative in
patients with MF cancer, while, in the remaining cases of
MF and in all MC tumors, formal mastectomy with imme-
diate reconstruction was performed. Axillary surgery con-
sisted in the SLNB performed by radioguided technique,
followed by AD. Each hot SLN (lymph nodes with counts
of > 10 times that of the background counts) was excised
and immediately examined with consecutive 200 μm fro-
zen sections and, regardless from the result of SLN status,
routine axillary dissection was performed in all patients.
Definitive histopathological examination was performed
on SLNs by routine hematoxylin-eosin staining com-
pleted by immunohistochemistry for cytokeratin just in
doubtful cases. According to the revised TNM staging sys-
tem of the American Joint Cancer Commission, the SLN
was considered positive when a metastatic focus > 0.2 mm
in diameter was found on frozen sections and/or on
definitive histopathology examination.
If preoperative MF or MC invasive breast cancer diagnosis
was not confirmed on the surgical specimen examination,
patients were excluded from the study.
Results
Between January 2004 and December 2005, 292 patients
underwent breast surgery for cancer at the Department of
Surgery of the University of Insubria. Among these
women, 35 patients had preoperative diagnosis of infil-
trating MF or MC breast carcinoma; 2 cases were excluded
from the study due to clinically positive axilla, confirmed
by ultrasound.
The remaining 33 patients were enrolled in the study, and
other 2 patients were excluded at the definitive pathologic
examination, due to a suspected second focus of ductal
carcinoma in situ (DCIS) in one patient and atypical duc-
tal hyperplasia (ADH) in the other one.
The remaining 31 patients (all female, mean age 64.1 ±
11.6) had confirmed MF (n = 12) or MC (n = 19) infiltrat-
ing cN0 breast carcinoma. The first 15 patients of this
series received a double intradermal radioisotope injec-
tion over the two most distant neoplastic nodules (2ID
Group), while the remaining 16 patients underwent peri-
areolar injection (A Group).
Lymphoscintigraphic anatomy
In the 2ID Group the lymphoscintigraphic study after
each injection showed the pattern of lymphatic spreading
from two different sites of the breast. In 14 (93.3%) cases
(4 MF, 10 MC) the (tratto più distale) pathway of diffusion
and the affering SLN(s) were common.
As shown in figure 1, the tracer, even when injected in dif-
ferent quadrants of the breast, migrated in the upper outer
quadrant were converged into a unique lymphatic chan-
nel which terminated in one or more SLN(s). In only one
(6.7%) case of MC cancer two different dominant path-
ways were present along the upper outer quadrant of the
breast (figure 2), each of them affering to a different SLN.
In the A Group lymphoscintigraphy showed one main
lymphatic trunk connecting subareolar plexus to one or
more SLN(s) in 15 out of 16 cases (93.7%), while in one
patient two different lymphatic channels started from are-
ola and each one ended separately at a different SLN.
Breast tumors features
In 31 patients affected by MF (n = 12) or MC (n = 19) infil-
trating breast cancer the number of lesions at preoperative
assessment were 2 in 28 cases, 3 in 2 patients and 4 in the
remaining one, while histology on surgical specimens
revealed 2 lesions in 23 cases, 3 in 6 cases and 4 in 2 cases.
Mean diameter of the largest nodule was 23.3 ± 10.1 (10World Journal of Surgical Oncology 2006, 4:79 http://www.wjso.com/content/4/1/79
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÷ 60) mm. Patients were classified as: T1, T2 and T3 in 15
(48.4%), 15 (48.4%) and 1 (3.2%) cases, respectively.
Breast conserving surgery was performed with radical mar-
gins in 8 patients with MF cancer, while the remaining
74.2% of cases (4 MF and all 19 MC tumors) underwent
mastectomy with immediate reconstruction (except for 3
patients who refused plastic surgery). After SLNB, three
levels AD was performed in all patients (mean number of
lymph nodes excised per patient: 17.9 ± 6.2).
Accuracy of SLNB in MF-MC tumors
Using radioisotope technique SLN was identified in all 31
cases (100% identification rate) in both groups. The mean
number of SLNs detected was 2.1 ± 0.9 (1–4), without any
difference between the 2ID (2.1 ± 0.9) and A Group (2.06
± 0.9). Histology of SLN from frozen sections was con-
firmed at definitive pathologic exam in all but one patient
(96.8% accuracy rate), in which micrometastasis in the
SLN was revealed at definitive histopathological exam
alone.
At least one positive SLN was found in 13 (41.9%) out of
31 patients with MF-MC invasive breast cancer: 9 mac-
rometastases (> 2 mm in size) and 4 (30.7%) micrometas-
tases (unique neoplastic focus from 0.2 to 2 mm in size).
No case of isolated tumoral cells (ITC) was detected.
In 7 out of 13 (53.8%) patients with positive SLN (includ-
ing all 4 cases of micrometastatic SLN), such a node was
the only site of metastases. SLN status correctly predicted
complete axillary status in 30 out of 31 patients; indeed in
one patient with 2 negative SLNs, one positive first level
lymph node (metastatic focus measuring 11 mm in diam-
eter) was demonstrated after complete AD. However, this
positive non radioactive lymph node had been already
identified by the surgeon as strongly suspicious for skip
metastasis [16,17].
Including this case as a false negative (FN) result, the FN
rate was 7.1% (1 out of 14), and sensitivity, negative pre-
dictive value and accuracy of SLNB in MF-MC invasive
breast cancer were 92.8%, 94.4% and 96.8%, respectively.
Discussion
During the last years the SLNB technique has replaced
routine AD as standard of care for lymph node staging of
breast cancer [18]. Excellent accuracy of the technique
with low false negative rate is well established in small,
unifocal, clinically node-negative tumors, in absence of
contraindications such as previous breast or axillary sur-
gery, neoadjuvant chemotherapy, chest-wall irradiation.
To date, SLNB represents a minimally invasive, highly
accurate method of axillary staging, which allows almost
65–70% patients to be spared from AD and its related
morbidity [19]. Patients affected by MF and MC breast
carcinoma are excluded from SLNB in most international
guidelines, due to concerns about a possible multiple pat-
tern of lymphatic spreading from different neoplastic
nodules of the breast. However, searching for the best
Lymphoscintigraphic study performed in a patient affected by  invasive MC breast cancer (two nodules located in the upper  outer and inner quadrants of the left breast) Figure 1
Lymphoscintigraphic study performed in a patient affected by 
invasive MC breast cancer (two nodules located in the upper 
outer and inner quadrants of the left breast). The patient 
underwent two subsequent lymphoscintigraphies after each 
intradermal injection of the tracer over the two neoplastic 
foci (2ID Group), showing one sentinel lymphatic channel 
affering to the same SLN. A) First lymphoscintigraphy per-
formed after the first radioisotope injection over the tumoral 
focus located in the upper outer quadrant of the breast. One 
SLN is visualized in the axilla. B) Second lymphoscintigraphy 
performed in the same patient after the second radioisotope 
injection over the other tumoral focus located in the upper 
inner quadrant of the breast. The same but hotter SLN is vis-
ualized in the axilla.World Journal of Surgical Oncology 2006, 4:79 http://www.wjso.com/content/4/1/79
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technique of SLN mapping stimulated further develop-
ments in the field of functional lymphatic anatomy [20].
Historically, under the nipple-areola complex a rich lym-
phatic network (Sappey plexus) seems to receive the
lymph from the whole breast and then drains to the axilla
[21], while according to studies from others the lymphat-
ics in the gland are directly connected to the axilla [22].
Although controversies remain about the course of lymph
flow between breast parenchyma and axilla, the theory of
the breast considered as a single lymphatic unit, at least
for what concerns axillary SLN, it is now widely accepted.
The correspondence of lymphatic drainage between the
deep glandular and the overlying skin in the same quad-
rant of the breast has been already demonstrated [23].
Such a "lobary" theory of lymphatic anatomy allowed the
diffusion of the intradermal injection of the marker for
SLN identification as the best option technique because of
the optimal identification rate of SLN [14,16].
More recently, a correspondence between peritumoral
and areolar injection has also been demonstrated. Regard-
less from tumor location within the breast, in over 90% of
cases the periareolar injection technique detects the same
SLN(s) which is identified by the peritumoral injection
using two different markers (radioisotope and blue dye)
[9,15,24,25]. Furthermore, also the use of areolar injec-
tion techniques as compared to the classical peritumoral
provides better results in terms of identification rates of
SLN and equal or even better accuracy [26-28].
Lymphoscintigraphic study of Kern et al., [29] gives the
anatomic support to the "whole breast" theory of axillary
lymphatic drainage, demonstrating a single (91%) main
lymphatic route (the so-called "sentinel lymphatic chan-
nel") draining from the rich areolar plexus to the SLN.
If the deep lymphatic drainage leads to the same SLN(s)
of the overlying skin, and the common pathway of this
superficial plexus is represented by a sentinel lymphatic
Lymphoscintigraphic study performed in a patient affected by invasive MC breast cancer (two nodules located in the upper  outer and inner quadrants of the left breast) Figure 2
Lymphoscintigraphic study performed in a patient affected by invasive MC breast cancer (two nodules located in the upper 
outer and inner quadrants of the left breast). The patient underwent two subsequent lymphoscintigraphies after each intrader-
mal injection of the tracer over the two neoplastic foci (2ID Group), showing two sentinel lymphatic channels mainly affering 
to different SLNs. A) First lymphoscintigraphy performed after the first radioisotope injection over the tumoral focus located 
in the upper outer quadrant of the breast. One SLN is visualized in the axilla. An other LN shows low radioactivity. B) Second 
lymphoscintigraphy performed in the same patient after the second radioisotope injection over the other tumoral focus 
located in the upper inner quadrant of the breast. One different pathway is visualized traversing the outer upper quadrant of 
the breast, which is mainly connected to the second SLN visualized after the first injection.World Journal of Surgical Oncology 2006, 4:79 http://www.wjso.com/content/4/1/79
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channel connecting the areola to the axilla, the SLN
should be considered representative of the whole breast,
thus overcoming concerns about the accuracy of the tech-
nique in case of MF and MC breast cancers.
Although the existence of a sentinel lymphatic channel
has been demonstrated by Kern et al., by using the areolar
injection technique [29], the present study gives the first
evidence that intradermal radioisotope injections in two
different quadrants of the breast give the same SLN visual-
ization in most of the cases. Furthermore, the lympho-
scintigrapic study performed in the present series
demonstrates in both 2ID and A groups a common final
pathway of the superficial lymphatic plexus of the breast
toward the axilla in over 90% of cases, regardless the site
of injection.
The common lymphatic pathway of drainage theory for
the whole skin envelope of the breast can explain the sim-
ilar results in term of high accuracy of SLNB in MF and MC
cancer reported in this and others series [30-38].
As shown in Table 1, despite of high variability among dif-
ferent studies, all retrospective series [34-36] and multi-
centric trials [32,37,38] report high accuracy and low false
negative rates (< 10%) of SLNB in MF and MC breast can-
cer. Tousimis et al., reported a false negative rate of 8%,
falling to 0% once T3 tumors and intraoperative palpable
axillary disease (according to our experience) are excluded
[17].
Goyal et al., in the ALMANAC trial retrospectively evalu-
ated the accuracy of the technique in 75 patients, finding
a 8.8% false negative rate. However, SLNB is compared
with node sampling instead of a complete AD in most
patients and diagnosis of MF-MC cancer was retrospec-
tively obtained only at final pathologic specimens [37].
More recently, a large prospective multi-institutional trial
of the Austrian Sentinel Node Study Group was reported
by Knauer et al., [38]. In this study the false negative rate
of SLNB in 150 MC cancer, 125 of whom underwent AD,
was 4.1%, not too far from the one reported in our study.
The prospective monoinstitutional series published in the
literature, although performed in small patients popula-
tions [30,31,11,33], report excellent results in all but one
study [33], where Ozmen et al., show a 33% false negative
rate in MF breast cancers. However, the value of this study
is limited by the fact that only MF cancers were enrolled
(MC tumors were excluded) and the majority of the cases
of this series (18 of 21) had only retrospective, pathologic
diagnosis of multifocality.
A possible explanation for this unique unacceptable
result, it may be due to technical reasons related to the use
of blue dye alone as tracer, injected through peritumoral
route, with a very low success rate in SLN identification
(85.7%). The Authors can only conclude that "SLNB using
peritumoral blue-dye injection method is not reliable to
be performed in patients with MF disease".
In our experience both areolar (A) and double intrader-
mal (2ID: over the two dominant tumors) injection tech-
niques have demonstrated equally feasible in MF-MC
tumors: no differences have been shown in success rate,
lymphoscintigraphic anatomy and mean number of SLNs
identified. However, 2 ID technique was used mainly for
the lymphoscintigraphic study aimed to evaluate the
route of lymphatic spreading from different sites of the
Table 1: Summary of validation studies of SLNB in MF-MC breast tumors published in the Literature, 1999–2006
Author year Study n. pts Mapping technique ID % FN % ACC %
Mertz30 1999 Prospective 16 A* 98 0 100
Schrenk31 2001 Prospective 19 Ablue +/- A* 100 0 100
Kim11 2002 Case reports 5 1ID* + Tblue 100 nv nv
Fernandez32 2002 Multicentric trial 53 T*+blue or ID*+blue or A*+blue 98 0 100
Ozmen33 2002 Prospective 21 MF Tblue 85,7 33,3 77,8
Kumar34 2003 Retrospective 59 (48 AD) Tblue + 1–2ID* 93,5 0 100
Tousimis35 2003 Retrospective 70 T*+blue 95,9 8 96
Kumar36 2004 Retrospective 10 (8 AD) T* or A*+blue 100 0 100
Goyal37 2004 Multicentric trial 75 (AD or S) T*+blue 94,6 8,8 95,8
Knauer38 2006 Multicentric trial 150 (125 AD) ns (* or/+blue) ns 4,1 97,4
Current study 2006 Prospective 31 2ID* or A* 100 7,1 96,8
A = areolar injection of radioisotope (A*) or blue dye (Ablue)
ID = intradermal injection of radioisotope (ID*) or blue dye (IDblue) over one (1ID) or two (2ID) neoplastic foci
T = peritumoral injection of radioisotope (T*) or blue dye (Tblue)
ns = non specified
AD = axillary dissection
S = lymph node samplingWorld Journal of Surgical Oncology 2006, 4:79 http://www.wjso.com/content/4/1/79
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breast. Once demonstrated that both pathway converged
into one sentinel lymphatic channel in over 90% of cases,
it appears useless and time-consuming to use more than
one site of injection (with double dose of radioactivity).
Although a single ID injection over the largest-size lesion
has been used in others' experience in case of MF-MC
tumors with similar results, areolar injection has the fur-
ther advantage of being independent from the location of
the nodules, which facilitates the procedure, especially in
case of non-palpable lesions.
To date our series is the largest monoinstitutional pro-
spective study on SLNB in MF-MC invasive breast cancer
and the high accuracy (96.8%) is comparable to other dif-
ferently designed series. Moreover, since surgeons are
aware of the possibility of a skip metastasis due to neo-
plastic obstruction of lymphatic vessels afferent to the true
SLN [16,17], during a routine procedure of SLNB a non
radioactive but suspicious LN would be removed and fro-
zen sections could reveal the positive status of axilla. On
this basis, if the contraindication to SLNB due to clinically
N+ finding is considered both for preoperative and intra-
operative diagnosis, the case of skip metastases identified
by the surgeon in our study has to be considered excluded
from the study, giving a FN rate of 0%, and all sensitivity,
negative predictive value and accuracy of 100%.
Conclusion
Our lymphoscintigraphic study demonstrated that axil-
lary SLN represents the whole breast regardless of tumor
location within the parenchyma. MF and MC breast can-
cers should not be considered anymore a contraindication
for the SLNB technique. Radioisotope injection through
areolar route can be proposed as the best option mapping
technique for MF-MC tumors.
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